A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Eli Lilly and Company
Fudan University
Coherus Oncology, Inc.
I-Mab Biopharma US Limited
AstraZeneca
UNICANCER
NuCana plc
Memorial Sloan Kettering Cancer Center
Imugene Limited
IGM Biosciences, Inc.
Memorial Sloan Kettering Cancer Center
Tyme, Inc
Taiho Pharmaceutical Co., Ltd.
Ruijin Hospital
OHSU Knight Cancer Institute
Asan Medical Center
Hoosier Cancer Research Network
National Cancer Institute, Naples
Ludwig-Maximilians - University of Munich
Federation Francophone de Cancerologie Digestive
GSO Global Clinical Research BV
Translational Oncology Research International
Grupo Espanol Multidisciplinario del Cancer Digestivo
AIO-Studien-gGmbH
UNICANCER
UNICANCER
University of Florida
American College of Radiology Imaging Network
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Daiichi Sankyo
Eli Lilly and Company
mAbxience Research S.L.
Sixth Affiliated Hospital, Sun Yat-sen University
Abramson Cancer Center at Penn Medicine
Epidemiological and Clinical Research Information Network
M.D. Anderson Cancer Center
Amgen
Sun Yat-sen University
Galectin Therapeutics Inc.
UNC Lineberger Comprehensive Cancer Center
City of Hope Medical Center
H. Lee Moffitt Cancer Center and Research Institute
Alliance for Clinical Trials in Oncology
Washington University School of Medicine
Georgetown University
Huashan Hospital
Alliance for Clinical Trials in Oncology
Sixth Affiliated Hospital, Sun Yat-sen University
M.D. Anderson Cancer Center
Sanofi